JPRN-UMIN000026224已完成未知
Efficacy of IOP reduction and safety of Mikeluna combination ophthalmic solution switched from Xalatan 0.005% and Mikelan LA 1%,2% ophthalmic solution. - Efficacy of IOP reduction and safety of Mikeluna combination ophthalmic solution switched from Xalatan 0.005% and Mikelan LA 1%,2% ophthalmic solution.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •some corneal abnormality or other diseases which may interfere with accurate IOP measurement history of glaucoma surgery contraindicated to Beta blockers
研究者
相似试验
招募中
不适用
Efficacy of IOP reduction and safety of Mikeluna combination ophthalmic solution switched from Xalacom combination ophthalmic solution.JPRN-UMIN000026231Inouye Eye Hospital100
已完成
不适用
Efficacy of IOP reduction and safety of Mikeluna combination ophthalmic solution switched from Xalatan 0.005% ophthalmic solution.JPRN-UMIN000026230Inouye Eye Hospital100
已完成
不适用
Efficacy of IOP reduction and safety of Eybelis ophthalmic solution 0.002% switched from Prostaglandin analog.glaucoma or ocular hypertensionJPRN-UMIN000035193Inouye Eye Hospital77
招募中
不适用
Efficacy of IOP reduction and safety of Eybelis ophthalmic solution 0.002%glaucoma or ocular hypertensionJPRN-UMIN000035240Inouye Eye Hospital100
暂停
3 期
EPOCIM in benign prostatic hyperplasia.Benign prostatic hyperplasiaRPCEC00000092Center of Molecular Immunology(CIM)306